

**BioXcel Therapeutics, Inc.**

555 Long Wharf Drive  
New Haven, CT 06511

January 19, 2024

***Via EDGAR***

Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, DC 20549  
Attention: Cindy Polynice

Re: **BioXcel Therapeutics, Inc.**  
**Registration Statement on Form S-3 Filed January 12, 2024**  
**File No. 333-276488**

To the addressee set forth above:

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, BioXcel Therapeutics, Inc. (the “*Company*”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-276488) be accelerated by the Securities and Exchange Commission to 4:30 p.m. Washington D.C. time on January 22, 2024 or as soon as practicable thereafter.

The Company requests that we be notified of such effectiveness by a telephone call to Peter N. Handrinos of Latham & Watkins LLP at (617) 948-6060 or Keith L. Halverstam of Latham & Watkins LLP at (212) 906-1761 and that such effectiveness also be confirmed in writing.

Sincerely,

**BioXcel Therapeutics, Inc.**

By: /s/ Richard Steinhart  
Richard Steinhart  
Chief Financial Officer

cc: Peter N. Handrinos, Latham & Watkins LLP  
Keith L. Halverstam, Latham & Watkins LLP  
N. Danny Shulman, Latham & Watkins LLP  
Gregory M. Drozdal, Latham & Watkins LLP

---